Anzeige
Mehr »
Donnerstag, 17.07.2025 - Börsentäglich über 12.000 News
Klinisch validiert. Vertriebsbereit. Und kurz vor der FDA-Zulassung.
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
ACCESS Newswire
213 Leser
Artikel bewerten:
(1)

MD Clarity Debuts Its Revenue Recovery Services Offering to Empower Provider Organizations With End-to-End Revenue Maximization Solutions

SEATTLE, WASHINGTON / ACCESS Newswire / July 17, 2025 / MD Clarity, a leading provider of revenue optimization solutions, today announced the launch of its Revenue Recovery Services offering. This technology-enabled service empowers healthcare providers with end-to-end support to recover revenue lost to underpayments and denials.

MD Clarity Logo

MD Clarity Logo

The ever-increasing complexity of payer reimbursement methodologies, multitude of payer contracts managed by each healthcare organization, and opacity of claim resolution processes challenge providers to attain maximum reimbursement. MD Clarity's Revenue Recovery Services offering addresses these challenges by enabling providers to:

  • Identify payment variances systematically: Detect discrepancies between actual payer reimbursements and contracted rates, whether due to contractual underpayments or claim denials.

  • Increase net revenue: Leverage payer reimbursement specialists to manage the claim resolution process to increase cash recoveries, reduce first-pass claim denial rates, and maximize net revenue on future claims.

  • Access expert guidance: Receive best practices for navigating claim resolution processes and driving continuous revenue cycle improvement.

"We are thrilled to unveil our Revenue Recovery Services offering. Today's launch builds upon our advanced software by bringing providers a true end-to-end solution for collecting from payers the revenue they have underpaid or erroneously denied," said Dan Freeman, MD Clarity's CEO. "The specialized expertise of our Revenue Recovery Services team brings providers a capable partner in improving claim resolution outcomes and fixing revenue leaks to drive net revenue growth and better financial health."

MD Clarity's Revenue Recovery Services provides healthcare organizations with an end-to-end solution for maximizing net revenue. Powered by MD Clarity's RevFind software, which systematically detects discrepancies between actual reimbursements and contracted rates, Revenue Recovery Services delivers a unified technology and expert services platform. This integrated approach enables providers to recover revenue lost to denials and underpayments, and implement ongoing improvements to prevent future revenue shortfalls.

With the introduction of its Revenue Recovery Services offering, MD Clarity continues to demonstrate its commitment to empowering healthcare providers with the tools, technologies, and support they need to thrive in today's complex healthcare landscape.

About MD Clarity

MD Clarity is a powerful software and services platform transforming the revenue cycle of healthcare organizations. Through pre-service patient estimates and deposits, automated detection of variances between payer payments and contracted rates, managed care agreement rate benchmarking and scenario modeling, and end-to-end revenue recovery services, MD Clarity enables the Revenue Cycle, Managed Care, and Finance teams of healthcare organizations to boost cash flow. With a decade-long track record capturing the complexities of managed care agreements within its software platform, MD Clarity has grown to serve more than 150,000 providers. For more information, visit MDClarity.com or follow MD Clarity on LinkedIn.

Contact Information

David Freeman
Senior Director of Strategy
david.freeman@mdclarity.com

.

SOURCE: MD Clarity



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/md-clarity-debuts-its-revenue-recovery-services-offering-to-empower-p-1049145

© 2025 ACCESS Newswire
Hensoldt, Renk & Rheinmetall teuer
Rheinmetall, Renk und Hensoldt haben den Rüstungsboom der letzten Jahre dominiert, doch inzwischen sind diese Titel fundamental heillos überbewertet. KGVs jenseits der 60, KUVs über 4, und das in einem politisch fragilen Umfeld mit wackelnder Haushaltsdisziplin. Für späteinsteigende Anleger kann das teuer werden.

Doch es gibt Alternativen, die bislang unter dem Radar fliegen; solide bewertet, operativ stark und mit Nachholpotenzial.

In unserem kostenlosen Report zeigen wir dir, welche 3 Rüstungsunternehmen noch Potenzial haben und wie du von der zweiten Welle der Zeitenwende profitieren kannst, ohne sich an überhitzten Highflyer zu verbrennen.

Holen Sie sich den neuesten Report! Verpassen Sie nicht, welche Aktien besonders vom weltweiten Aufrüsten profitieren dürften, und laden Sie sich das Gratis-PDF jetzt kostenlos herunter.

Dieses exklusive Angebot gilt aber nur für kurze Zeit! Daher jetzt downloaden!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.